| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1525-1403.2007.00128.X |
| P698 | PubMed publication ID | 22150890 |
| P50 | author | James C. Eisenach | Q29791450 |
| P2093 | author name string | Mark Wallace | |
| Michael Cousins | |||
| Nagy Mekhail | |||
| Robert Levy | |||
| Timothy Deer | |||
| Michael Saulino | |||
| Michael Stanton-Hicks | |||
| Peter Staats | |||
| Elliot S Krames | |||
| Richard Rauck | |||
| Michael Erdek | |||
| David Caraway | |||
| Eric Buchser | |||
| K Dean Willis | |||
| Samuel J Hassenbusch | |||
| Phillip Kim | |||
| Sunil Panchal | |||
| Kenneth Follett | |||
| James Rathmell | |||
| Allen Burton | |||
| Eric Grigsby | |||
| Joshua Prager | |||
| Lisa Stearns | |||
| Marc Huntoon | |||
| William Witt | |||
| Gladstone McDowell | |||
| Anne Ver Donck | |||
| Leong Liem | |||
| Stuart Dupen | |||
| Todd Sitzman | |||
| P2860 | cites work | Intrathecal baclofen overdose and withdrawal. | Q51212983 |
| Intrathecal adenosine administration: a phase 1 clinical safety study in healthy volunteers, with additional evaluation of its influence on sensory thresholds and experimental pain. | Q51490776 | ||
| The stability of mixtures of morphine hydrochloride, bupivacaine hydrochloride, and clonidine hydrochloride in portable pump reservoirs for the management of chronic pain syndromes. | Q51630691 | ||
| A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. | Q51982361 | ||
| Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump: a case report | Q24801987 | ||
| Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) | Q28182735 | ||
| A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine | Q28580405 | ||
| Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data | Q30923879 | ||
| Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy | Q32147900 | ||
| Intrathecal adenosine increases spinal cord blood flow in the rat: measurements with the laser-Doppler flowmetry technique | Q33208254 | ||
| Antinociceptive interactions between intrathecal gabapentin and MK801 or NBQX in rat formalin test | Q33599590 | ||
| Interaction between intrathecal gabapentin and adenosine in the formalin test of rats | Q33631764 | ||
| Antihyperalgesic and side effects of intrathecal clonidine and tizanidine in a rat model of neuropathic pain | Q44453673 | ||
| Preclinical work leading to the development of spinal analgesia | Q44491595 | ||
| Safety of chronic intrathecal morphine infusion in a sheep model | Q44491600 | ||
| Uterine cervical distension induces cFos expression in deep dorsal horn neurons of the rat spinal cord | Q44491607 | ||
| A comparison of the neurotoxic effects on the spinal cord of tetracaine, lidocaine, bupivacaine, and ropivacaine administered intrathecally in rabbits | Q44521008 | ||
| Systemic, but not intrathecal ketorolac is antinociceptive to uterine cervical distension in rats | Q44589938 | ||
| Spinal cord lesion after long-term intrathecal clonidine and bupivacaine treatment for the management of intractable pain | Q44702065 | ||
| Antinociceptive and neurotoxicologic screening of chronic intrathecal administration of ketorolac tromethamine in the rat. | Q44704865 | ||
| The antinociceptive potencies and interactions of endogenous ligands during continuous intrathecal administration: adenosine, agmatine, and endomorphin-1. | Q44741328 | ||
| Effect of K+ channel modulators on the antiallodynic effect of gabapentin | Q44743017 | ||
| Evidence-based review of the literature on intrathecal delivery of pain medication | Q34034073 | ||
| Clinical guidelines for intraspinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000. | Q34034080 | ||
| Future directions in the management of pain by intraspinal drug delivery | Q34034087 | ||
| Comparative pharmacology of the ketamine isomers. Studies in volunteers | Q34197358 | ||
| Repeated dosing with oral allosteric modulator of adenosine A1 receptor produces tolerance in rats with neuropathic pain | Q34314050 | ||
| Phase I safety assessment of intrathecal injection of an American formulation of adenosine in humans | Q34468168 | ||
| Tonic inhibitory role of alpha4beta2 subtype of nicotinic acetylcholine receptors on nociceptive transmission in the spinal cord in mice | Q34539248 | ||
| Intrathecal ziconotide for refractory chronic pain | Q34548850 | ||
| Inhibitory effect of gabapentin on N-methyl-D-aspartate receptors expressed in Xenopus oocytes | Q34577754 | ||
| Hemodynamic effects of gabapentin in rats | Q34659217 | ||
| Spinal alpha(2)-adrenergic and muscarinic receptors and the NO release cascade mediate supraspinally produced effectiveness of gabapentin at decreasing mechanical hypersensitivity in mice after partial nerve injury | Q35100897 | ||
| Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance – a case report and review of literature | Q35541011 | ||
| Intrathecal morphine for chronic benign pain | Q35551558 | ||
| Opioid Therapy for Chronic Pain | Q35582306 | ||
| Moxonidine, a mixed alpha(2)-adrenergic and imidazoline receptor agonist, identifies a novel adrenergic target for spinal analgesia | Q35694978 | ||
| Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study | Q35752995 | ||
| The use of intrathecal midazolam in humans: a case study of process | Q35779434 | ||
| Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-- report of an expert panel | Q35785670 | ||
| Epidural and intrathecal analgesia is effective in treating refractory cancer pain | Q35887529 | ||
| Ropivacaine: a pharmacological review | Q36106850 | ||
| Mechanisms of nociception evoked by intrathecal high-dose morphine | Q36152348 | ||
| A review of intrathecal morphine therapy related granulomas | Q36167357 | ||
| Clinical application of adenosine and ATP for pain control | Q36201169 | ||
| Intrathecal hydromorphone for intractable nonmalignant pain: a retrospective study | Q36419664 | ||
| A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain | Q36483190 | ||
| The use of neuraxial adjuvant drugs (neostigmine, clonidine) in obstetrics | Q36492979 | ||
| Intrathecal baclofen therapy in children | Q36569689 | ||
| Transient neurological syndrome: does it really exist? | Q36615723 | ||
| Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication | Q36764202 | ||
| Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model | Q37405398 | ||
| A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia | Q37416417 | ||
| Intrathecal bupivacaine for chronic pain: a review of current knowledge | Q37965863 | ||
| A prospective randomized double-blind trial of the use of intrathecal fentanyl in patients undergoing lumbar spinal surgery | Q39344697 | ||
| The use of continuous intrathecal infusion of octreotide in patients with chronic pain of noncancer origin: an evaluation of efficacy in a prospective double-blind fashion | Q39345495 | ||
| Intrathecal but not intravenous opioids release adenosine from the spinal cord | Q44771162 | ||
| Continuous intrathecal infusion of hydromorphone: safety in the sheep model and clinical implications | Q44783564 | ||
| Spinal G-protein-gated K+ channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia. | Q44804066 | ||
| Does gabapentin act as an agonist at native GABA(B) receptors? | Q44832413 | ||
| Antiallodynic effects of systemic and intrathecal morphine in the spared nerve injury model of neuropathic pain in rats. | Q44846850 | ||
| Characteristic of interactions between intrathecal gabapentin and either clonidine or neostigmine in the formalin test | Q44856701 | ||
| Spinal adenosine receptor activation reduces hypersensitivity after surgery by a different mechanism than after nerve injury | Q44869905 | ||
| Intrathecal ketorolac in dogs and rats | Q44894576 | ||
| Intrathecal opioids and lower urinary tract function: a urodynamic evaluation | Q44913132 | ||
| Sex differences in systemic morphine analgesic tolerance following intrathecal morphine injections | Q44948817 | ||
| Intrathecal morphine and inflammatory masses | Q44954371 | ||
| Respiratory distress after intrathecal baclofen withdrawal | Q44998580 | ||
| A comparison of intrathecal plain solutions containing ropivacaine 20 or 15 mg versus bupivacaine 10 mg. | Q45033966 | ||
| Drug stability testing to support clinical feasibility investigations for intrathecal baclofen-clonidine admixture. | Q45035680 | ||
| Efficacy of intrathecal bupivacaine: how important is the flow rate? | Q45058933 | ||
| Intrathecal morphine, but not buprenorphine or pentazocine, can induce spastic paraparesis after a noninjurious interval of spinal cord ischemia in the rat. | Q45122133 | ||
| Intrathecal baclofen withdrawal: emergent recognition and management | Q45122544 | ||
| Dextromethorphan potentiates morphine antinociception at the spinal level in rats | Q45138581 | ||
| Stability of clonidine in clonidine-hydromorphone mixture from implanted intrathecal infusion pumps in chronic pain patients | Q45180894 | ||
| Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system | Q45180896 | ||
| Intrathecal baclofen withdrawal syndrome caused by low residual volume in the pump reservoir: a report of 2 cases | Q45191244 | ||
| Analysis of interactions between serotonin and gabapentin or adenosine in the spinal cord of rats | Q45208258 | ||
| Effects of adenosine agonist R-phenylisopropyl-adenosine on halothane anesthesia and antinociception in rats | Q45233278 | ||
| Intrathecal morphine reduces allodynia after peripheral nerve injury in rats via activation of a spinal A1 adenosine receptor | Q45245128 | ||
| Intrathecal catheter tip inflammatory mass: a failure of clonidine to protect | Q45282898 | ||
| The spinal nitric oxide involved in the inhibitory effect of midazolam on morphine-induced analgesia tolerance | Q45290377 | ||
| Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial | Q46080589 | ||
| Pruritus after intrathecal baclofen withdrawal: A retrospective study | Q46368783 | ||
| Intrathecal neostigmine prevents intrathecal clonidine from attenuating hypercapnic cerebral vasodilation in rabbits | Q46395565 | ||
| Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats | Q46395582 | ||
| Effect of systemic and intrathecal gabapentin on allodynia in a new rat model of postherpetic neuralgia | Q46432106 | ||
| Synergic antinociceptive interaction between tramadol and gabapentin after local, spinal and systemic administration | Q46484535 | ||
| A novel approach to prevent repeated catheter migration in a patient with a baclofen pump: a case report | Q46491754 | ||
| Long-term intrathecal S(+)-ketamine in a patient with cancer-related neuropathic pain | Q46542033 | ||
| Attenuation of morphine tolerance by intrathecal gabapentin is associated with suppression of morphine-evoked excitatory amino acid release in the rat spinal cord | Q46626448 | ||
| Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate | Q46644034 | ||
| Neurologic sequelae of intraspinal drug delivery systems: results of a survey of american implanters of implantable drug delivery systems | Q46696438 | ||
| Evaluation of interaction between intrathecal adenosine and MK801 or NBQX in a rat formalin pain model | Q46706577 | ||
| Antinociception of intrathecal adenosine receptor subtype agonists in rat formalin test | Q46769667 | ||
| Adenosine reduces glutamate release in rat spinal synaptosomes | Q46775039 | ||
| A single dose of intrathecal morphine in rats induces long-lasting hyperalgesia: the protective effect of prior administration of ketamine. | Q46814793 | ||
| The antiallodynic action target of intrathecal gabapentin: Ca2+ channels, KATP channels or N-methyl-d-aspartic acid receptors? | Q46861880 | ||
| The nitric oxide-cyclic GMP-protein kinase G-K+ channel pathway participates in the antiallodynic effect of spinal gabapentin | Q46913128 | ||
| Ketorolac prevents recurrent withdrawal induced hyperalgesia but does not inhibit tolerance to spinal morphine in the rat. | Q46920951 | ||
| Spinal cord compression in a patient with a pain pump for failed back syndrome: a chalk-like precipitate mimicking a spinal cord neoplasm: case report | Q46931164 | ||
| Intrathecal catheter granuloma associated with isolated baclofen infusion | Q46956071 | ||
| Intrathecal S(+)-ketamine in refractory neuropathic cancer pain | Q46972625 | ||
| Depression, night terrors, and insomnia associated with long-term intrathecal clonidine therapy | Q48476853 | ||
| No neurotoxicity from long-term (>5 years) intrathecal infusion of midazolam in humans | Q48683870 | ||
| Intrathecal catheter granuloma with baclofen infusion. | Q51092743 | ||
| Severe toxic damage to the rabbit spinal cord after intrathecal administration of preservative-free S(+)-ketamine | Q39345543 | ||
| Efficacy of intrathecal adenosine for postoperative pain relief | Q39354342 | ||
| Opioid-related side-effects after intrathecal morphine: a prospective, randomized, double-blind dose-response study. | Q39354348 | ||
| Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain | Q39354418 | ||
| Plasma concentrations of meperidine and normeperidine following continuous intrathecal meperidine in patients with neuropathic cancer pain | Q39368130 | ||
| Multiple lead spinal cord stimulation for chronic mechanical low back pain: a comparative study with intrathecal opioid drug delivery | Q39375556 | ||
| Intrathecal morphine infusion for chronic non-malignant pain: a multiple center retrospective survey | Q39375560 | ||
| Intrathecal baclofen as adjuvant therapy to enhance the effect of spinal cord stimulation in neuropathic pain: a pilot study | Q39379400 | ||
| Supraspinal and spinal cord opioid receptors are responsible for antinociception following intrathecal morphine injections | Q39382391 | ||
| Treatment of neuropathic cancer pain with continuous intrathecal administration of S +-ketamine | Q39383791 | ||
| Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial | Q39386029 | ||
| Outcome of intrathecal opioids in chronic non-cancer pain | Q39412310 | ||
| Stability, compatibility, and safety of intrathecal bupivacaine administered chronically via an implantable delivery system | Q39414008 | ||
| The long-term antinociceptive effect of intrathecal S(+)-ketamine in a patient with established morphine tolerance | Q39414281 | ||
| Methadone in the intrathecal treatment of chronic nonmalignant pain resistant to other neuroaxial agents: the first experience | Q39423649 | ||
| Intrathecal baclofen for the treatment of intractable spasticity of spine or brain etiology | Q39431571 | ||
| Long-term intrathecal administration of midazolam and clonidine | Q39467069 | ||
| Intraspinal morphine for chronic pain: a retrospective, multicenter study | Q39467494 | ||
| Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases | Q39469174 | ||
| Octreotide: a potent new non-opiate analgesic for intrathecal infusion | Q39502633 | ||
| Dextromethorphan potentiates morphine-induced antinociception at both spinal and supraspinal sites but is not related to the descending serotoninergic or adrenergic pathways. | Q40461707 | ||
| Epidural neostigmine produces analgesia but also sedation in women after cesarean delivery | Q40536164 | ||
| Intrathecal granuloma after implantation of a morphine pump: case report and review of the literature | Q41589335 | ||
| Histopathology and evaluation of potentiation of morphine-induced antinociception by intrathecal droperidol in the rat | Q41818300 | ||
| Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report | Q42542434 | ||
| Management of intrathecal catheter-tip inflammatory masses: a consensus statement | Q42625419 | ||
| Intrathecal granuloma and intramedullary abscess associated with an intrathecal morphine pump | Q42723041 | ||
| A Prospective, Open-label Study of Long-term Intrathecal Ziconotide for Chronic Nonmalignant Back Pain: A Case Report | Q42723049 | ||
| Chemical Stability of Admixtures Combining Ziconotide with Morphine or Hydromorphone During Simul ated Intrathecal Administration | Q42723050 | ||
| Stability and Analgesic Efficacy of Di-acetyl Morphine (Diamorphine) Compared with Morphine in Implanted Intrathecal Pumps In Vivo | Q42723064 | ||
| Efficacy and Safety of Intrathecal Opioid/Bupivacaine Mixture in Chronic Nonmalignant Pain: A Double Blind, Randomized, Crossover, Multicenter Study by the National Forum of Independent Pain Clinicians (NFIPC). | Q42723086 | ||
| Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation | Q43493912 | ||
| Intrathecal bupivacaine with morphine or neostigmine for postoperative analgesia after total knee replacement surgery | Q43667418 | ||
| Long-term intrathecal infusion of drug combinations for chronic back and leg pain. | Q43750736 | ||
| Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system | Q43818734 | ||
| Neurologic complications including paralysis after a medication error involving implanted intrathecal catheters | Q43867138 | ||
| Effect of intrathecal octreotide on thermal hyperalgesia and evoked spinal c-Fos expression in rats with sciatic constriction injury | Q44198272 | ||
| The addition of droperidol or clonidine to epidural tramadol shortens onset time and increases duration of postoperative analgesia | Q44298431 | ||
| Effects of chronic intrathecal infusion of a partial differential opioid agonist in dogs | Q44300355 | ||
| Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology | Q44342427 | ||
| Remote nerve injection of mu opioid receptor adeno-associated viral vector increases antinociception of intrathecal morphine | Q44349594 | ||
| Spinal L-type calcium channel blockade abolishes opioid-induced sensory hypersensitivity and antinociceptive tolerance | Q44351081 | ||
| Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence | Q44422482 | ||
| P433 | issue | 4 | |
| P921 | main subject | pain management | Q621261 |
| drug delivery | Q1392806 | ||
| P304 | page(s) | 300-328 | |
| P577 | publication date | 2007-10-01 | |
| P1433 | published in | Neuromodulation | Q15758089 |
| P1476 | title | Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel | |
| P478 | volume | 10 |
| Q45018233 | A Prospective, Randomized, Single-Blinded, Head-to-Head Long-Term Outcome Study, Comparing Intrathecal (IT) Boluses With Continuous Infusion Trialing Techniques Prior to Implantation of Drug Delivery Systems (DDS) for the Treatment of Severe Intract |
| Q37996441 | A history of intraspinal analgesia, a small and personal journey |
| Q36556921 | Adenosine A(1) receptors in mouse pontine reticular formation depress breathing, increase anesthesia recovery time, and decrease acetylcholine release. |
| Q48098883 | Aseptic arachnoiditis in a patient treated with intrathecal morphine infusion: symptom resolution on switch to ziconotide |
| Q34399168 | Best practices for intrathecal drug delivery for pain |
| Q42679273 | Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study. |
| Q39258887 | Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients |
| Q43763677 | Cost impact of intrathecal polyanalgesia |
| Q38727831 | Current and Future Issues in the Development of Spinal Agents for the Management of Pain |
| Q37738293 | Current developments in intraspinal agents for cancer and noncancer pain |
| Q52595844 | Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice. |
| Q37815434 | Effective treatments for pain in the older patient |
| Q45254142 | Effects of flow rate modifications on reported analgesia and quality of life in chronic pain patients treated with continuous intrathecal drug therapy |
| Q36236169 | Efficacy and Safety of Ropivacaine Addition to Intrathecal Morphine for Pain Management in Intractable Cancer |
| Q28084722 | Evidence-based Clinical Practice Guidelines for Interventional Pain Management in Cancer Pain |
| Q39261367 | Experience in treatment of patients with neuropathic facial pain using ziconotide |
| Q36110458 | Failed back surgery syndrome: a suggested algorithm of care |
| Q37965890 | Future directions for intrathecal pain management: a review and update from the interdisciplinary polyanalgesic consensus conference 2007. |
| Q37744893 | Implications of opioid analgesia for medically complicated patients |
| Q47914210 | In vitro stability of low-concentration ziconotide alone or in admixtures in intrathecal pumps |
| Q34147371 | Increased risk of suicide under intrathecal ziconotide treatment? – A warning |
| Q35794710 | Interventional management of neuropathic pain: NeuPSIG recommendations |
| Q37639925 | Intraspinal techniques for pain management in cancer patients: a systematic review |
| Q35973565 | Intrathecal Drug Delivery Systems for Cancer Pain: A Health Technology Assessment |
| Q35973569 | Intrathecal Drug Delivery Systems for Noncancer Pain: A Health Technology Assessment |
| Q47598071 | Intrathecal Hydromorphone and Bupivacaine Combination Therapy for Post-Laminectomy Syndrome Optimized with Patient-Activated Bolus Device |
| Q38037058 | Intrathecal bupivacaine for head and neck pain |
| Q43067849 | Intrathecal catheter granuloma associated with continuous sufentanil infusion |
| Q38151939 | Intrathecal drug administration in chronic pain syndromes |
| Q37956953 | Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates |
| Q39259434 | Intrathecal midazolam as supplementary analgesia for chronic lumbar pain--15 years' experience |
| Q36110427 | Neuraxial (epidural and intrathecal) opioids for intractable pain |
| Q42089567 | Optimizing pain control through the use of implantable pumps |
| Q37246868 | Pain management for hepatobiliary cancer |
| Q37737302 | Pain relief in palliative care: a focus on interventional pain management |
| Q37011060 | Painful boney metastases |
| Q54294050 | Physician response to medtronic's position on the use of off-label medications in the synchromed pump. |
| Q38050501 | Polyanalgesic Consensus Conference 2012. |
| Q30039702 | Polyanalgesic Consensus Conference 2012: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel |
| Q34267381 | Polyanalgesic Consensus Conference--2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). |
| Q38030985 | Polyanalgesic Consensus Conference--2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain |
| Q27004010 | Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain |
| Q39257838 | Psychiatric predisposition to autonomic and abnormal perception side-effects of ziconotide: a case series study. |
| Q37944866 | Role of pretrial systemic opioid requirements, intrathecal trial dose, and non-psychological factors as predictors of outcome for intrathecal pump therapy: one clinician's experience with lumbar postlaminectomy pain |
| Q38198087 | Safety and efficacy of intrathecal drug delivery for pain |
| Q37261060 | Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain |
| Q48610809 | Spinal cord stimulation (SCS) in conjunction with peripheral nerve field stimulation (PNfS) for the treatment of complex pain in failed back surgery syndrome (FBSS). |
| Q38013181 | Spinal mechanisms of pain and analgesia |
| Q42844798 | Stability and Tolerability of High Concentrations of Intrathecal Bupivacaine and Opioid Mixtures in Chronic Noncancer Pain: An Open-Label Pilot Study |
| Q48255167 | Successful reversal of hyperalgesia/myoclonus complex with low-dose ketamine infusion |
| Q38405012 | Sufentanil versus fentanyl: efficacy and patient satisfaction with intrathecal pain management |
| Q37605352 | Targeting voltage-gated calcium channels for neuropathic pain management |
| Q37899194 | Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development |
| Q30396983 | The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines |
| Q37803291 | The Use of Spinal Cord Stimulation and Intrathecal Drug Delivery in the Treatment of Low Back-Related Pain |
| Q37999476 | The delayed appearance of neurological signs in intrathecal granuloma warrants imaging surveillance: a case series and review of the literature |
| Q38356496 | The evidence of neuraxial administration of analgesics for cancer-related pain: a systematic review |
| Q44295791 | The failed and future promise of intraspinal drug administration for neurologic disorders |
| Q39220283 | The median local analgesic dose of intrathecal bupivacaine with hydromorphone for labour: a double-blind randomized controlled trial |
| Q46419998 | The role of epidural phenol in cancer patients at the end of life |
| Q38197250 | The use of intrathecal baclofen in pain management |
| Q38220447 | Treatment of medically refractory cancer pain with a combination of intrathecal neuromodulation and neurosurgical ablation: case series and literature review |
| Q38727837 | Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials |
| Q39190886 | Ziconotide Trialing by Intrathecal Bolus Injections: An Open-Label Non-Randomized Clinical Trial in Postoperative/Posttraumatic Neuropathic Pain Patients Refractory to Conventional Treatment |
| Q37736046 | Ziconotide for treatment of severe chronic pain |
Search more.